NCT05805618View on ClinicalTrials.gov

Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Gastroenteritis
Interventions
BIOLOGICAL

Recombinant Norovirus Hexavalent Vaccine

To prevent acute gastroenteritis caused by norovirus of genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17

OTHER

Matching Placebo

matching placebo for Recombinant Norovirus Hexavalent Vaccine / KH002

Sponsors

Lead Sponsor

Syneos Health
All Listed Sponsors
collaborator

Chengdu Kanghua Biological Products Co., Ltd

INDUSTRY

lead

Syneos Health

OTHER

NCT05805618 - Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects | Biotech Hunter | Biotech Hunter